Search results for "ErbB"

showing 10 items of 298 documents

2018

Oncogenic human papillomaviruses (HPV) are small DNA viruses that infect keratinocytes. After HPV binding to cell surface receptors, a cascade of molecular interactions mediates the infectious cellular internalization of virus particles. Aside from the virus itself, important molecular players involved in virus entry include the tetraspanin CD151 and the epidermal growth factor receptor (EGFR). To date, it is unknown how these components are coordinated in space and time. Here, we studied plasma membrane dynamics of CD151 and EGFR and the HPV16 capsid during the early phase of infection. We find that the proteinase ADAM17 activates the extracellular signal-regulated kinases (ERK1/2) pathway…

Keratinocytes0301 basic medicineCarcinogenesisvirusesEndocytic cycle610 MedizinTetraspanin610 Medical sciencesEpidermal growth factor receptorBiology (General)InternalizationPapillomaviridaemedia_commonHuman papillomavirus 16Microbiology and Infectious DiseaseADAM17General NeuroscienceQRoncogenic PapillomavirusGeneral MedicineEndocytosisCell biologyErbB ReceptorsCapsidMedicinemicrodomainsResearch ArticleHumanQH301-705.5MAP Kinase Signaling SystemSciencemedia_common.quotation_subject030106 microbiologyADAM17 ProteinTetraspanin 24BiologyGeneral Biochemistry Genetics and Molecular BiologyVirus03 medical and health sciencesCell surface receptorViral entrygrowth factorsHumansGeneral Immunology and MicrobiologyCell MembranePapillomavirus InfectionsVirionentry receptor complexCell BiologyVirus Internalizationtetraspanin030104 developmental biologybiology.proteinHeLa CellseLife
researchProduct

Melittin Modulates Keratinocyte Function through P2 Receptor-dependent ADAM Activation

2012

Melittin, the major component of the bee venom, is an amphipathic, cationic peptide with a wide spectrum of biological properties that is being considered as an anti-inflammatory and anti-cancer agent. It modulates multiple cellular functions but the underlying mechanisms are not clearly understood. Here, we report that melittin activates disintegrin-like metalloproteases (ADAMs) and that downstream events likely contribute to the biological effects evoked by the peptide. Melittin stimulated the proteolysis of ADAM10 and ADAM17 substrates in human neutrophil granulocytes, endothelial cells and murine fibroblasts. In human HaCaT keratinocytes, melittin induced shedding of the adhesion molecu…

KeratinocytesCell SurvivalBlotting WesternADAM17 ProteinP2 receptorBiologyModels Biologicalcomplex mixturesBiochemistryMelittinCell LineADAM10 ProteinMicechemistry.chemical_compoundTransactivationAdenosine TriphosphateAnimalsHumansPhosphorylationExtracellular Signal-Regulated MAP KinasesReceptorMolecular BiologyCells CulturedMice KnockoutDose-Response Relationship DrugReverse Transcriptase Polymerase Chain ReactionPurinergic receptorHEK 293 cellstechnology industry and agricultureMembrane ProteinsCell BiologyFibroblastsCadherinsEmbryo MammalianMelittenCell biologyErbB ReceptorsADAM ProteinsHaCaTHEK293 CellschemistryPhosphorylationlipids (amino acids peptides and proteins)Receptors Purinergic P2X7Amyloid Precursor Protein SecretasesJournal of Biological Chemistry
researchProduct

Shuttling of the autoantigen La between nucleus and cell surface after uv irradiation of human keratinocytes.

1990

During the past years we have established that the nuclear autoantigen La shuttles between the nucleus and the cytoplasm in tumor cells after inhibition of transcription or virus infection. We reinvestigated this shuttling using primary human keratinocytes from both healthy donors and patients with xeroderma pigmentosum. Ultraviolet irradiation resulted in both an inhibition of transcription and a translocation of La protein from the nucleus to the cytoplasm. After a prolonged inhibition of transcription La protein relocated into the nucleus and assembled with nuclear storage regions. The uv-induced shuttling included a translocation to the cell surface, where La protein colocalized with ep…

KeratinocytesCytoplasmTranscription GeneticUltraviolet RaysCellFluorescent Antibody TechniqueBiologyAutoantigensTranscription (biology)Epidermal growth factormedicineHumansNuclear proteinCell NucleusEpidermal Growth FactorCell MembraneBiological TransportCell BiologyCell biologyErbB ReceptorsCell nucleusmedicine.anatomical_structureBiochemistryRibonucleoproteinsCytoplasmProtein BiosynthesisKeratinocyteNucleusExperimental cell research
researchProduct

Pore-forming Staphylococcus aureus alpha-toxin triggers epidermal growth factor receptor-dependent proliferation.

2006

Staphylococcal alpha-toxin is an archetypal killer protein that homo-oligomerizes in target cells to create small transmembrane pores. The membrane-perforating beta-barrel motif is a conserved attack element of cytolysins of Gram-positive and Gram-negative bacteria. Following the recognition that nucleated cells can survive membrane permeabilization, a profile of abundant transcripts was obtained in transiently perforated keratinocytes. Several immediate early genes were found to be upregulated, reminiscent of the cellular response to growth factors. Cell cycle analyses revealed doubling of S + G2/M phase cells 26 h post toxin treatment. Determination of cell counts uncovered that after an …

KeratinocytesStaphylococcus aureusSrc Homology 2 Domain-Containing Transforming Protein 1ImmunologyCellBacterial ToxinsBlotting WesternFluorescent Antibody TechniqueTransfectionMicrobiologyCell LineHemolysin ProteinsDownregulation and upregulationNucleated cellVirologymedicineHumansGrowth factor receptor inhibitorEpidermal growth factor receptorStaphylococcus aureus alpha toxinAdaptor Proteins Signal TransducingCell Line TransformedCell ProliferationbiologyCytotoxinsReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCell CycleCell cycleFlow CytometryTransmembrane proteinCell biologyErbB Receptorsmedicine.anatomical_structureShc Signaling Adaptor Proteinsbiology.proteinMitogensSignal TransductionCellular microbiology
researchProduct

The Neuronal Nitric Oxide Synthase Is Upregulated in Mouse Skin Repair and in Response to Epidermal Growth Factor in Human HaCaT Keratinocytes

2004

Expression of nNOS mRNA was found in normal human and mouse skin tissue. Upon wounding, we observed a rapid downregulation of nNOS mRNA and protein in wounds of mice; however, when repair continued, nNOS mRNA was strongly upregulated and nNOS protein expression peaked at late stages of healing. Immunohistochemistry revealed wound keratinocytes as the cellular source of nNOS. In line with the in vivo situation, we found a basal expression of nNOS in the human keratinocyte cell line HaCaT. A marked stimulation of nNOS expression in the cells was achieved with epidermal growth factor receptor (EGFR) ligands such as epidermal growth factor (EGF), heparin-binding EGF, transforming growth factor-…

Keratinocytesinorganic chemicalsReceptor ErbB-3Receptor ErbB-2medicine.medical_treatmentwound healingNitric Oxide Synthase Type IDermatologyBiochemistryGene Expression Regulation EnzymologicCell LineMiceDownregulation and upregulationnitric oxideEpidermal growth factormedicineAnimalsHumansRNA MessengerEpidermal growth factor receptorMolecular BiologySkinMice Inbred BALB CEpidermal Growth Factorintegumentary systembiologyGrowth factorgrowth factorCell BiologyUp-RegulationCell biologyErbB Receptorsbody regionsNitric oxide synthaseHaCaTmedicine.anatomical_structurenervous systemImmunologycardiovascular systembiology.proteinNeuregulinNitric Oxide SynthaseKeratinocyteSignal TransductionJournal of Investigative Dermatology
researchProduct

Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.

2010

Monoclonal antibodies (mAbs) constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The treatment of B-cell malignancies and HER2/Neu(+) breast cancer has benefited considerably from the use of therapeutic mAbs, either alone or in combination with standard chemotherapy. Frequent relapses, however, demonstrate that the bioactivity of these mAbs is still suboptimal. The concept of improving the anti-tumor activity of mAbs is well established and potentiating the cytotoxicity induced by anticancer mAbs can be achieved by strategies that target the downstream cytolytic effector cells. The recruitment of Fcγ receptor-dependent functi…

Killer Cells NaturalReceptor ErbB-2NeoplasmsT-LymphocytesReceptors IgGAntibody-Dependent Cell CytotoxicityAnimalsAntibodies MonoclonalHumansγδ T Cells ImmunotherapyReceptors Antigen T-Cell gamma-deltaImmunotherapyLymphocyte ActivationCurrent molecular medicine
researchProduct

Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis.

2008

Abstract Background Obesity in postmenopausal women is associated with increased breast cancer risk, development of more aggressive tumors and resistance to certain anti-breast cancer treatments. Some of these effects might be mediated by obesity hormone leptin, acting independently or modulating other signaling pathways. Here we focused on the link between leptin and HER2. We tested if HER2 and the leptin receptor (ObR) can be coexpressed in breast cancer cell models, whether these two receptors can physically interact, and whether leptin can transactivate HER2. Next, we studied if leptin/ObR can coexist with HER2 in breast cancer tissues, and if presence of these two systems correlates wi…

LeptinTranscriptional Activationmedicine.medical_specialtyCancer ResearchReceptor ErbB-2Breast Neoplasmslcsh:RC254-282Breast cancerSurgical oncologyRisk FactorsInternal medicineCell Line TumormedicineGeneticsHumansObesityReceptorskin and connective tissue diseasesneoplasmsLeptin receptorbusiness.industryLeptinCarcinoma Ductal BreastReceptor Cross-Talklcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticPostmenopauseEndocrinologyOncologyImmunohistochemistryReceptors LeptinFemaleSignal transductionbusinessImmunostainingProtein BindingResearch ArticleBMC cancer
researchProduct

Multisciplinary management of patients with liver metastasis from colorectal cancer

2016

Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to res…

Liver metastase0301 basic medicinemedicine.medical_specialtyChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor; Epidermal Growth Factor; GastroenterologyColorectal cancermedicine.medical_treatmentAngiogenesis InhibitorsColorectal NeoplasmReviewChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor Epidermal Growth Factor; GastroenterologyMetastasis03 medical and health sciencesLiver metastases0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCombined Modality TherapyChemotherapyHepatectomyHumansDisease management (health)ChemotherapyAntineoplastic Combined Chemotherapy ProtocolLiver resectionEpidermal Growth Factorbusiness.industryGeneral surgeryHepatobiliary diseaseLiver NeoplasmsGastroenterologyDisease ManagementGeneral MedicineMultidisciplinary teammedicine.diseaseColorectal cancerCombined Modality TherapyRadiation therapyErbB Receptors030104 developmental biologyLiver Neoplasm030220 oncology & carcinogenesisReceptor Epidermal Growth FactorHuman medicineHepatectomybusinessColorectal NeoplasmsAngiogenesis InhibitorHumanReceptor
researchProduct

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

2010

The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs. Several molecular alterations have been defined as "driver mutations". These are responsible for both the initiation and maintenance of the malignancy. The epidermal growth factor receptor (EGFR) pathway is the main regulator of cell function and cancer development. It has a widely defined role in the occurrence of driver mutations. Up till now EGFR gene mutations, KRAS gene mutations and EML4-ALK fusion genes are the most widely recognized alterations involved in both the biology and the clinical management of lung adenocarcinoma. In th…

Lung NeoplasmsOncogene Proteins FusionSettore MED/06 - Oncologia MedicaEGFRGene ExpressionAdenocarcinomaGene mutationmedicine.disease_causeProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesPredictive Value of TestsProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsmedicineAdenocarcinoma of the lungHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyEpidermal growth factor receptorTyrosine kinase inhibitorsMutationbiologybusiness.industryDriver mutationGeneral MedicineProtein-Tyrosine KinasesPrognosismedicine.diseaseErbB ReceptorsTreatment OutcomeOncologyMutationImmunologyras ProteinsCancer researchbiology.proteinAdenocarcinomaKRASCarcinogenesisbusinessTyrosine kinaseAlgorithmsCancer Treatment Reviews
researchProduct

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

2014

Abstract: Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, even in long-lasting responses, resistance to EGFR TKIs invariably occurs. Areas covered: This review examines resistance mechanisms to EGFR TKI treatment, which mainly arise from secondary EGFR mutations. Other resistance-inducing processes include mesenchymal-epithelial transition factor (MET) amplification, epithelial-mesenchymal transformation, phenotypic change from NSCLC to small-cell lung carcinoma, and modifications in parallel signalling pathways. Current…

Lung NeoplasmsSettore MED/06 - Oncologia MedicaAfatinibNovel therapeutic strategiesLapatinibmedicine.disease_causeNSCLCT790Mchemistry.chemical_compoundErbB ReceptorsCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansRadiology Nuclear Medicine and imagingEpidermal growth factor receptorProtein Kinase InhibitorsEGFR inhibitorsbiologybusiness.industryEGFR mutations; TKI inhibitors resistance; NSCLC; New drugs; Novel therapeutic strategiesGeneral MedicineNew drugEGFR mutationsCombined Modality TherapyDacomitinibrespiratory tract diseasesErbB ReceptorsNew drugsOncologychemistryDrug Resistance NeoplasmCancer researchbiology.proteinKRASHuman medicineEGFR mutationbusinessmedicine.drugTKI inhibitors resistanceCancer Treatment Reviews
researchProduct